Shots:
- Sandoz has launched Tyruko, a biosimilar version of Biogen’s Tysabri (natalizumab), for all indications of the reference product, incl. relapsing forms of multiple sclerosis (MS) & mod. to sev. active Crohn’s disease in adults
- In 2019, Sandoz signed a global commercialization deal with Polpharma for Tyruko, with Polpharma responsible for development & manufacturing of the drug substance, while Sandoz holds exclusive global commercialization & distribution rights in all markets
- Additionally, Sandoz has partnered with Labcorp to develop & validate a laboratory-developed test for detecting anti-JCV antibodies, & through the Tyruko JCV testing program, Labcorp will offer the test at no cost to eligible pts, with Sandoz covering all expenses
Ref: Sandoz | Image: Sandoz | Press Release
Related News:- EirGenix Enters ~$152M Licensing Deal with Sandoz to Commercialize EG1206A (Biosimilar, Perjeta)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
